Related Experiment Videos
[Mechanisms of prostate cancer recurrence]
Atsushi Mizokami1, Mikio Namiki
1Department of Urology, Kanazawa University.
Abstract:
Androgen-deprivation therapy is often the first choice of several therapeutic procedures for advanced prostate cancer. However, despite an initial response to androgen-deprivation therapy, the cancer eventually progresses from an androgen-dependent to an androgen-independent phenotype. Molecular mechanism of development to androgen-independence and recurrence during androgen-deprivation therapy remain unclear. The observation that heterogeneity of AR expression in prostate cancer correlates with malignancy suggests that androgen responsiveness plays an important key role in the progression of prostate cancer. Therefore, it is very important to consider the role of AR and mechanisms of relapse when we treat androgen-independent prostate cancer.
Insights
Androgen-deprivation therapy is a common prostate cancer treatment. Understanding how cancer becomes androgen-independent is crucial for treating recurrence.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Context:
- Advanced prostate cancer often initially responds to androgen-deprivation therapy (ADT).
- Prostate cancer can progress to an androgen-independent state despite ADT.
- The molecular mechanisms driving this progression and recurrence remain unclear.
Purpose:
- To explore the role of androgen receptor (AR) expression heterogeneity in prostate cancer progression.
- To investigate the mechanisms underlying the development of androgen-independence and recurrence during ADT.
Summary:
- ADT is a primary treatment for advanced prostate cancer, but resistance develops.
- Heterogeneity in AR expression correlates with malignancy, indicating AR's key role.
- Understanding AR's role and relapse mechanisms is vital for treating androgen-independent prostate cancer.
Impact:
- Provides insights into the molecular basis of treatment resistance in prostate cancer.
- Highlights the importance of AR signaling in prostate cancer progression and recurrence.
- Informs the development of novel therapeutic strategies for advanced and recurrent prostate cancer.